The French pharmaceutical company will appeal the FDA's rejection of its Lemtrada multiple-sclerosis drug after the U.S. regulator expressed concern over serious side effects and the design of Sanofi's clinical trials.
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702304361604579289893471980218.html?mod=pls_whats_news_us_business_f
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702304361604579289893471980218.html?mod=pls_whats_news_us_business_f
Nessun commento:
Posta un commento